Subscribe To
SEEL / Seelos Therapeutics Releases the Itinerary for its Research and Development Update Conference Call and Webcast to be Held on December 15, 2022
Content Topics
Seelos
Therapeutics
Releases
Itinerary
Research
Development
Update
Conference
Webcast
December
Stock
SEEL
SEEL News
By PRNewsWire
October 27, 2023
Seelos Therapeutics to Present a Poster on SLS-005 in Alzheimer's Disease at Neuroscience 2023
-SLS-005 induces autophagy to reduce mutant protein aggregates, and is currently being studied in Alzheimer's disease, Huntington's disease, Amyotroph more_horizontal
By InvestorPlace
September 21, 2023
Why Is Seelos Therapeutics (SEEL) Stock Down 25% Today?
Seelos Therapeutics (NASDAQ: SEEL ) stock is falling on Thursday after the company released results from a clinical trial. Seelos Therapeutics first more_horizontal
By Proactive Investors
September 20, 2023
Seelos tumbles 66% as depression drug fails after it recruits too few patients
Seelos Therapeutics (NASDAQ:SEEL) Inc's share price plummeted by 66% pre-market after the company announced that its phase II study for SLS-002, a tre more_horizontal
By Market Watch
September 20, 2023
Seelos Therapeutics' stock slides 36% after trial of treatment for suicidal ideation has too few patients to meet endpoint
Seelos Therapeutics Inc.'s stock SEEL tumbled 36% in premarket trade Wednesday, after the company reported promising results from a trial of a treatme more_horizontal
By Seeking Alpha
July 12, 2023
Seelos: 2 Catalysts Before End Of 2023 Make This A Must Watch
Results from Part 2 of the phase 2 registration-directed study, using SLS-002 for acute suicidal ideation and behavior for MDD, are expected to be rel more_horizontal
By PRNewsWire
December 8, 2022
Seelos Therapeutics Releases the Itinerary for its Research and Development Update Conference Call and Webcast to be Held on December 15, 2022
NEW YORK , Dec. 8, 2022 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the developme more_horizontal
By Zacks Investment Research
December 6, 2022
3 Biotech Stocks Aiming to Reinvent Mental Health Treatment
Atai, Biogen, and Sage are working to develop new treatments for mental illness. more_horizontal